Introduction
The recent discovery of a second estrogen receptor, ERβ, shows that the mechanisms behind the effects of estrogen are far more complicated than previously assumed, and offers unique opportunities to gain a better understanding of these phenomena. ERβ is expressed in many important target tissues for estrogen, and a better insight into the respective mechanisms of action of estrogen receptor α (ERα) and ERβ might give clues concerning the etiology and pathogenesis of, for example, prostate or ovarian cancer. Furthermore, the development of ERα and ERβ specific ligands may open up interesting new possibilities for treatment of, for example, postmenopausal symptoms and breast cancer. In this review, we will try to summarize what is known so far about ERβ, with some emphasis on the human receptor and its expression. We will, furthermore, try so summarize what is known about different isoforms of the receptor, in view of what is known about isoforms and variants of other receptors, in particular ERα and the progesterone receptor (PR).
Estrogens
Estrogens influence growth, differentiation and function of many target tissues, including tissues of the male and female reproductive systems such as mammary gland, uterus, vagina, ovary, testis, epididymis and prostate (Clark et al. 1992) . Estrogens have also been shown to play important roles in bone maintenance (Turner et al. 1994) and in the cardiovascular system, where they have cardioprotective effects (Farhat et al. 1996) .
In the central nervous system (Mccarthy & Pfaus 1996) , estrogens influence both sexual/mating behavior and non-reproductive events including memory and learning. Natural and synthetic antagonists are used in a number of clinical applications, for example in breast cancer therapy, where the estrogen dependency of breast tumors is the key for intervention with antiestrogens such as tamoxifen. Use of estrogens in the treatment and prevention of osteoporosis and in estrogen replacement therapy of postmenopausal women is also common.
Estrogens are mainly produced in the ovaries and peripheral tissues. The three main forms of estrogens are 17β-estradiol (biologically the most potent), estriol and estrone. They diffuse in and out of cells, but are retained with high affinity and specificity in target cells by an intranuclear binding protein, termed the estrogen receptor (ER). This receptor regulates the expression of specific target genes by binding to target sequences called response elements in the promoter region of the respective target genes (Gronemeyer & Laudet 1995) .
The nuclear receptor superfamily includes, in addition to the steroid receptors, thyroid, retinoic acid and vitamin D 3 receptors. In addition, a large number of 'orphan' receptors have been identified, for which no ligands have been identified so far. This nuclear receptor superfamily has, as of today, approximately 70 known members, about two thirds of which are 'orphan' receptors (Enmark & Gustafsson 1996) .
The estrogen receptor
Analysis of the estrogen receptor and other steroid receptors shows that they can be subdivided into several functional domains (Beato et al. 1995) . The N-terminal A/B domain is highly variable in sequence and length, and usually contains a transactivation function, which activates target genes by interacting with components of the core transcriptional machinery. The DNA binding domain, also referred to as the C domain, contains two zinc fingers, which are involved in specific DNA binding and receptor dimerization. The hinge (D) domain contributes flexibility to the DNA via the ligand binding domain, and has also, in some cases, been shown to influence the DNA binding properties of individual receptors. The ligand binding domain (sometimes called the E domain) is relatively large and harbors regions important for ligand binding, receptor dimerization, nuclear localization and interactions with transcriptional coactivators and corepressors. Finally, the C-terminal F domain has been shown to contribute to the transactivation Estrogen receptor β − a novel receptor opens up new possibilities for cancer diagnosis and treatment capacity of the receptor, but its other functions, if any, are to a large extent unknown.
One estrogen receptor was cloned in 1986 from the uterus (Green et al. 1986 ). Soon thereafter it became a dogma that there existed only one single ER gene. This notion, however, was difficult to reconcile with the striking tissue-specific differences in action of synthetic estrogens and antiestrogens.
For many other members of the nuclear receptor superfamily multiple receptor subtypes have been identified, for instance in the case of the thyroid hormone and retinoic acid receptors as well as for many of the orphan receptors (Gronemeyer & Laudet 1995) .
Furthermore, when an ERα knock-out (ERKO) mouse was developed, specific estrogen binding was still observed in some tissues (Lubahn et al. 1993) . Surprisingly, in these ERKO mice, apart from large abnormalities in the reproductive organs, the gene deletion has little or no effect on, for example, bone stability or the cardiovascular system (Lubahn et al. 1993) . In retrospect, this suggested the existence of a second receptor for estrogen.
Estrogen receptor β
The cloning and initial characterization of rat ERβ was described in 1996 (Kuiper et al. 1996a) . ERβ is highly homologous to the previously identified mammalian estrogen receptor (consequently called ERα), particularly in the DNA binding domain (95% amino acid identity) and in the ligand binding domain (55% amino acid identity) (Fig. 1) .
Ligand binding experiments revealed high affinity, high specificity and low capacity binding of estradiol by ERβ, with a K d similar to that of ERα, 0.6 nM.
The ERβ protein is capable of stimulating transcription of an estrogen receptor target gene in a manner similar to ERα, using synthetic estrogen response elements in front of reporter genes.
Some natural and synthetic ligands show differences in binding affinity to ERα and ERβ, although many ligands bind with similar affinity. This suggests that it should be possible to develop ligands specific to either of the two subtypes. Determination of the three-dimensional crystal structures of the ERα and ERβ ligand binding domains (Brzozowski et al. 1997, authors' unpublished observations) have given further credence to this assumption, and are currently being used to design subtype-specific agonists and antagonists.
Interestingly, sequence comparison of all known estrogen receptors shows that these receptors form three groups, whilst the receptors cloned from fish constitute a separate subgroup. The exception in the fish subgroup is the ER cloned from Japanese eel, which actually represents an ERβ homolog (Todo et al. 1996) .
The question whether the third subgroup represents an 'ERγ', or if, in general, further subtypes of estrogen receptors exist is important. Mice with double knock-outs of both the ERα and ERβ genes will obviously be interesting to investigate in this respect. If specific estrogen binding can still be observed, this would make a strong case for the existence of further ER subtypes. In any event, it might be possible to identify evolutionary remnants, for example pseudogenes, corresponding to further ER subtypes in mammalian genomes.
In the rat, ERα shows the highest expression in uterus, testis, pituitary, ovary, kidney, epididymis and adrenal, and ERβ shows the highest expression in prostate, ovary, lung, bladder, brain and epididymis (Kuiper et al. 1996a,b) .
During the past two years, ERβ has also been cloned from human (Mosselman et al. 1996 , Enmark et al. 1997 , mouse (Tremblay et al. 1997) , marmoset monkey (Callitrix jacchus) (J Gaughan, unpublished results, Genbank no. Y09372) and Japanese eel (Todo et al. 1996) . Human ERβ in its translated portion shows approximately 89% identity to rat ERβ, 88% identity to mouse ERβ, and 47% identity to human ERα, a degree of similarity well in concordance with that observed for species homologs of other nuclear receptors. It can, however, be noted that the degree of homology between ERα and ERβ is low for two receptor subtypes, particularly in the ligand binding domain; in fact it is similar to the homology sometimes seen between two separate steroid receptors, for example the glucocorticoid and progesterone receptors.
Human ERβ
The distribution of ERβ in human tissues has been studied to various extents by many groups using different methods i.e. reverse transcription-PCR assay, in situ hybridization and immunohistochemistry. These studies have shown that ERβ is highly expressed in several human organs, both in reproductive and non-reproductive tissues (Fig. 2) . It is a great challenge for the future to clarify the function of estrogens in all these tissues, many of them sometimes referred to as 'non-targets' for estrogen.
In the female reproductive tissues, ERβ is found in the ovary, uterus, endometrium and breast. In the ovary, the receptor is localized to the stroma of the cortex as well as to the granulosa cells (Byers et al. 1997 , Enmark et al. 1997 . The granulosa cells apparently contain only ERβ mRNA. ERβ is thus likely to play an important role in the regulation of follicular growth and oocyte development. With in situ hybridization, ERβ can also be detected in the uterus, although to a lesser degree than ERα. In breast, the epithelium of the tubules expresses ERβ, and in some breast cancers ERβ is also present. It will be very interesting to determine if and how ERβ expression varies in these tissues under conditions such as pregnancy and lactation. In breast tumors the expression of ERα and ERβ seems to be present independently of each other (Dotzlaw et al. 1997) . Current diagnostic procedures for breast tumors utilize immunological techniques that only have the potential to detect ERα. In future characterization of tumors from breast it might be relevant to determine the expression of both estrogen receptors.
In the reproductive organs of the male, ERβ is expressed in the testis and in the prostate (Enmark et al. 1997) . In the testis, ERα has previously been reported to be expressed in the Leydig cells of the testis (Fischer et al. 1997) , where no or very little ERβ is present. In contrast, ERβ is expressed in developing spermatids, where ERα is absent.
During recent years, there has been an intensive debate concerning alleged effects of different xenobiotics on the reproductive ability of animals, particularly in fish and man. A class of compounds called 'environmental estrogens', including for example PCBs, has been in particular focus (Jobling et al. 1995) . We have shown that both ERα and ERβ may bind at least some of these compounds (Kuiper et al. 1996b . Although the affinity is relatively low, ERβ binds the xenoestrogens methoxychlor and bisphenol A with considerably higher affinity than ERα. As human ERβ is expressed in the developing spermatocytes of the testis, it is tempting to speculate that some of the claimed effects of environmental estrogens on fertility might be mediated via ERβ.
In the prostate, ERβ is expressed in the epithelial cells of the secretory alveoli. Interestingly, benign prostatic hyperplasia (BPH) usually originates from this cell type. Although the expression of ERβ in the human prostate seems to be lower than in the rat prostate, it might still be relevant for development and progression of BPH and prostate cancer. Tumors in the prostate are, initially, usually dependent on testosterone, and orchidectomy and anti-androgens have been used in the treatment of prostate cancer. Estrogens are also sometimes effective as treatment, unfortunately leading to an increased risk of cardiovascular complications. Prostatic hyperplasia is an extremely common condition among elderly men, the disease possibly linked to a shift in the balance between androgens and estrogens in the blood (Ekman 1995) .
Surprisingly, studies of ERKO mice (cf. above) show that the gene deletion has few or no effects on bone stability. Studies by our own and other groups have indeed shown that ERβ is expressed in osteoblasts of growing bone in the rat. ERβ is also detected in osteoblastic cell lines, pointing to a possible role of ERβ in bone formation (Onoe et al. 1997 , Arts et al. 1998 . The relevance of these observations in the human is, however, unclear, since the only known human patient lacking functional ERα displays severe osteoporosis (Smith et al. 1994) .
Using a carotid arterial injury model, it has been shown that in ERKO mice the vascular protective effect of estrogen is unchanged (Iafrati et al. 1997) . The authors conclude that the protective effect of estrogen is independent of ERα. We have found that ERβ, but not ERα, is expressed in human umbilical vein endothelial cells, a finding in line with these observations in mice.
Another example of a tissue where ERβ is expressed is the gastrointestinal tract, namely in the mucosa of the stomach, duodenum, colon and rectum (Enmark et al. 1997) . We have shown that ERβ has a relatively high affinity, considerably higher than ERα, for several plantderived substances with estrogenic activity, for example coumestrol and genistein (Kuiper et al. 1996b) . It is possible that ERβ expressed in the gastrointestinal tract is exposed to these compounds via the diet. For several years it has been suggested that estrogens may protect against colon cancer (Newcomb & Storer 1995) . Similar claims have also been made for diets containing soy protein, a product rich in phytoestrogens (Goldin et al. 1995) . Furthermore, estrogens have been shown to affect calcium uptake in the intestine through a poorly understood mechanism (Arjmandi et al. 1994) , and perhaps ERβ may mediate some of these effects.
In lymph nodes and in the cortex of the thymus, a large portion of the lymphocytes expresses ERβ (Enmark et al. 1997) . It has long been known that estrogens have important effects on the immune system. In particular in rodents, estrogens are important downregulators of lymphopoiesis, causing thymic involution during pregnancy or estrogen treatment; the opposite effect is seen upon ovariectomy. In humans, it is known that most autoimmune diseases are more common in women than in men (Lahita 1996) . Estrogens have also recently been reported to specifically inhibit thymocyte development (Rijhsinghani et al. 1997 ). An exciting possibility is that some of the immunomodulatory effects of estrogen might be mediated via ERβ.
Both ERα and ERβ are present in the brain, but ERβ seems to be the main estrogen receptor in the brain in, for example, the hypothalamus, the hippocampus and in several limbic regions (Li et al. 1997) . Effects of estrogens on the central nervous system have been known for many years. It has been claimed that estrogen replacement therapy reduces the risk of Alzheimer's disease in women, and can improve this condition, at least in some patients (Tang et al. 1996) . Furthermore, estrogen has been reported to improve cognitive functions in postmenopausal women. In some species, male sexual/mating behavior and the so-called masculinization of the brain are also estrogen-dependent. ERKO animals show deficiencies in reproductive behavior (Ogawa et al. 1996) but appear to have normal cognitive functions (Fugger et al. 1997) , and it will be interesting to study these behavioral aspects in ERβ knock-out animals, and to attempt to attribute certain estrogen effects in the central nervous system to either the ERα or ERβ subtype.
The ERβ gene
The exon/intron organization of both the mouse and human ERβ genes has been determined (Enmark et al. 1997) . All exon/intron boundaries are well conserved in the ERβ gene as compared with the human ERα gene (Fig. 3) . Notably, the only difference observed in the genomic organization of the ER genes is the intron present in the middle of the D domain of the ER isolated from rainbow trout and Oreochromis aureus, which is absent from both ERα and ERβ. The translated exons of the mouse ERβ gene span approximately 40 kb. The analysis of the human ERα gene has shown that it is a very large gene, with the translated exons spanning more than 140 kb (Ponglikitmongkol et al. 1988) . The ER genes from fish, however, are considerably smaller, spanning approximately 30 to 40 kb (LeRoux et al. 1993) . Our data show that the size of the ERβ gene is similar to that of the fish ERs. For other paralogous genes in the nuclear receptor superfamily, the gene size has been shown to vary at least to the same extent as for the ER subtypes. The peroxisome proliferator-activated receptor (PPAR) genes, for example, differ in size from 30 to 105 kb in the mouse. It has been speculated that the size of the introns might influence the transcriptional efficiency of a gene, particularly in situations of rapid cell division (O'Farrell 1992), a notion that might well be true for prokaryotes and lower eukaryotes, organisms with a short generation time. The relevance of this phenomenon for mammalian genes has never been verified.
The mouse ERβ gene has recently been mapped to mouse chromosome 12 using interspecific backcross analysis (Tremblay et al. 1997 ). This represents a chromosomal region homologous to 14q22-24, where the human ERβ gene is localized (Enmark et al. 1997) . Since the human ERα gene is located on the long arm of chromosome 6, this definitely excludes the possibility of differential splicing to explain the formation of the ERβ subtype. 14q22-24 is close to a recently identified gene associated with early onset of Alzheimer's disease (Sherrington et al. 1995) and this region is also frequently involved in rearrangements in human uterine leiomyoma and in neoplasms of the kidney. A more detailed mapping of this chromosomal region as well as studies on patient material will, in time, tell whether this chromosomal localization of ERβ has any relevance with reference to the diseases mentioned.
Isoforms and variants of the estrogen receptor
All subtypes of the estrogen receptor show very complex patterns at the level of transcriptional control. ERα has been shown in different species to have at least two or three separate promoters with different but overlapping tissue distribution (Grandien et al. 1995) . In the Oreochromis aureus ER, one of the estrogen receptors isolated from fish, two alternative polyadenylation sites located approximately 300 bp apart have been found, in addition to two different transcription start sites (Tan et al. 1996) . Both mouse and human ERβ give several bands of very different sizes in Northern blot experiments (Enmark et al. 1997 , Tremblay et al. 1997 , corresponding to sizes between 3.5 and 9.5 kb, indicating that the ERβ gene also contains multiple promoters and/or polyadenylation signals.
In addition, several groups have recently reported on isoforms of ERβ with reference to the coding part of the gene, isoforms which differ either in the amino terminus (Ogawa et al. 1998) or in the ligand binding domain (Chu & Fuller 1997) . One question which is still under debate is which initiation methionine(s) is preferentially used in translation of the ERβ protein. In the human gene, there are three different possible candidate methionines, and in mouse and rat there are four (Fig. 4) . These should give rise to proteins of slightly different sizes: 53, 54, 60 or 61 kDa respectively, and it has not yet been conclusively shown which ones exist in various situations. In the rat, Western blots show that the 55 kDa form is the most common in pregnant breast (T Rylander, unpublished data), whereas in the human there are reports of both 55 kDa and 59 kDa forms.
This situation is reminiscent of the human progesterone receptor isoforms, where it has long been established that two forms exist, PR-A and PR-B, which differ in their N-terminus. The two transcripts originate from the same exon, the transcription of the PR-A isoform originating from a position close to the initiation methionine of PR-B. These two forms have different transcriptional activation properties, where the shorter form, PR-A, is claimed to act as a repressor of PR-B function. The ratio between these two isoforms varies between different cell types and it is suggested to be of relevance for some of the tissue-specific actions of progestins (Syvala et al. 1997) .
The function of the N-terminal 'extension' of ERβ is at the moment unclear. This sequence is, however, extremely rich in potentially phosphorylatable serine and proline residues.
For ERα, there are numerous examples of variant receptors, either with point mutations at a single amino acid or with insertions or (more commonly) deletions. Most of these mutant receptors are found in various cancers, and previous work on these has not yet convincingly shown that these receptor variants are essential in estrogen mechanism of action.
Recently, evidence is beginning to accumulate of parallel phenomena for ERβ. The most solid data describe a variant ERβ with an insertion of 18 amino acids in the ligand binding domain (Chu & Fuller 1997) . In in vitro experiments, this isoform binds estradiol with a much lower affinity than the canonical ERβ receptor. There is also a recent report of a variant ERβ with a deletion in the beginning of the ligand binding domain (Vladusic et al. 1998) .
Furthermore, there are a number of unpublished reports of other deletions and substitutions in ERβ. No study has yet been conducted to investigate the degree of polymorphism in the normal population, but as yet nothing indicates that the number of ERβ variants is not at least as large as for ERα.
No biological function for these isoforms has as yet been defined. In the nuclear receptor superfamily such isoforms are relatively common, particularly in the Nterminal domain, and have been extensively studied for the retinoic acid receptors (Gronemeyer & Laudet 1995) . Before attributing too much weight to the ERβ isoforms it is mandatory that their presence should be assessed not only at the mRNA level but also at the protein level.
Heterodimerization
The recent discovery that an additional estrogen receptor subtype (ERβ) is present in various rat, mouse and human tissues has significantly advanced our understanding of the mechanisms underlying estrogen signaling.
We and others have reported that ERα and ERβ are able to form heterodimers, both in solution and when bound to DNA, the formation of heterodimers being greatly enhanced by the presence of ligand (Pettersson et al. 1997) .
This suggests the existence of two previously unrecognised pathways of estrogen signaling; via ERβ in cells exclusively expressing this subtype and via ERα/ERβ heterodimers in cells expressing both ER subtypes. It cannot be excluded that ERβ homodimers interact with novel response elements, apart from the known estrogen response slements (EREs). It must also be kept in mind that only a few of the estrogen-regulated genes contain classical EREs. Both ERα and ERβ may activate genes via binding to AP1 sites, and it has recently been shown that the two receptor subtypes do indeed show differences when acting through this element (Paech et al. 1997) . Interestingly, on this response element, tamoxifen shows opposite effects with ERα and ERβ, acting as an antagonist in the former case but as an agonist in the latter case. These results may help to explain the paradoxical effects of tamoxifen, an antagonist in some tissues (e.g. the breast) but an agonist in others (e.g. the endometrium). This is also in agreement with the observation that tamoxifen treatment increases the risk of developing endometrial cancer.
The existence of two ER subtypes greatly expands the physiological regulatory potential of estrogenic hormones. Different target cells may respond differently to the same hormonal stimulus due to alternative composition of receptors. Varying ratios of ERα and ERβ proteins in different cells, resulting in different populations of homo-and heterodimers could constitute a hitherto unrecognised mechanism involved in tissue and cell type specific actions not only of estrogens but also of antiestrogens.
Conclusions
Estrogen has a key role in many biological phenomena such as cellular differentiation, homeostasis and reproduction. This is in line with the multitude of different pathological conditions associated with changes in the production of estrogen and/or the cellular response to these stimuli. Osteoporosis, cancer of the breast, endometrium and prostate, and atherosclerosis are some examples of diseases where estrogen receptors may be involved. Our recent discovery of ERβ shows that the mechanisms behind the effects of estrogen are far more complicated than previously assumed, and offers unique opportunities to gain a better understanding of these phenomena. ERβ is expressed in many important target tissues for estrogen, and development of ERα and ERβ specific ligands opens up interesting new possibilities for treatment of, for example, postmenopausal symptoms and breast cancer.
